Genetic Signatures Ltd (GSS) - Total Liabilities
Based on the latest financial reports, Genetic Signatures Ltd (GSS) has total liabilities worth AU$4.95 Million AUD (≈ $3.50 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Genetic Signatures Ltd cash conversion from operations to assess how effectively this company generates cash.
Genetic Signatures Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how Genetic Signatures Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Genetic Signatures Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Genetic Signatures Ltd Competitors by Total Liabilities
The table below lists competitors of Genetic Signatures Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aterian Inc
NASDAQ:ATER
|
USA | $14.35 Million |
|
Skyline Investments Inc
TA:SKLN
|
Israel | ILA215.64 Million |
|
Sejin T.S Co.Ltd
KQ:067770
|
Korea | ₩1.08 Billion |
|
Hantop Inc
KQ:002680
|
Korea | ₩91.00 Billion |
|
Invesco Asia Dragon Trust plc
LSE:IAD
|
UK | GBX33.20 Million |
|
PT Mitra Pack Tbk
JK:PTMP
|
Indonesia | Rp104.19 Billion |
|
Wescan Goldfields Inc
V:WGF
|
Canada | CA$562.18K |
|
New Era Helium Inc Common Stock
NASDAQ:NEHC
|
USA | $10.49 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Genetic Signatures Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Genetic Signatures Ltd (GSS) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 3.60 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genetic Signatures Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genetic Signatures Ltd (2013–2025)
The table below shows the annual total liabilities of Genetic Signatures Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$4.54 Million ≈ $3.21 Million |
-26.62% |
| 2024-06-30 | AU$6.18 Million ≈ $4.38 Million |
+0.32% |
| 2023-06-30 | AU$6.16 Million ≈ $4.36 Million |
+27.04% |
| 2022-06-30 | AU$4.85 Million ≈ $3.43 Million |
+3.08% |
| 2021-06-30 | AU$4.71 Million ≈ $3.33 Million |
+24.33% |
| 2020-06-30 | AU$3.79 Million ≈ $2.68 Million |
+142.54% |
| 2019-06-30 | AU$1.56 Million ≈ $1.10 Million |
+29.07% |
| 2018-06-30 | AU$1.21 Million ≈ $855.77K |
+1.65% |
| 2017-06-30 | AU$1.19 Million ≈ $841.86K |
-7.30% |
| 2016-06-30 | AU$1.28 Million ≈ $908.13K |
+72.71% |
| 2015-06-30 | AU$743.14K ≈ $525.82K |
+100.59% |
| 2014-06-30 | AU$370.48K ≈ $262.13K |
-91.24% |
| 2013-06-30 | AU$4.23 Million ≈ $2.99 Million |
-- |
About Genetic Signatures Ltd
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, a… Read more